BioCorRx
- Company typePublic
- Founded2010
- HeadquartersAnaheim, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingServices
BioCorRx firmographics
Firmographics- Name
- BioCorRx
- Legal name
- BioCorRx Inc.
- Website
- https://biocorrx.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
BioCorRx industry classification
Industry- Product category
- Addiction Treatment Services
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (62142), Diet and Weight Reducing Centers (812191)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Residential Substance Use Rehabilitation (Inpatient Rehab) (HLAFACAE)
- akta.pro secondary industry
- Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring (HLAFALAN)
Keywords
Where BioCorRx is headquartered
LocationHeadquarters
- HQ city
- Anaheim
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioCorRx business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- LUCEMYRA (lofexidine) Sales: Following the acquisition of LUCEMYRA in March 2025, BioCorRx Pharmaceuticals Inc. generates revenue from the sale and distribution of LUCEMYRA, an FDA-approved non-opioid medication for mitigating opioid withdrawal symptoms. Revenue was $635,224 in Q3 2025 and $948,362 for the nine months ended September 30, 2025.
- Beat Addiction Recovery Program: Recovery program offered to independent treatment centers or physicians in the United States. The program includes proprietary CBT modules and peer recovery support, potentially along with prescribed medications. The company does not sell or manufacture pharmaceutical products itself.
- UnCraveRx Weight Loss Program: Medication-assisted weight loss program offered as a virtual health and wellbeing program with personalized human and digital support from wellness specialists.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
BioCorRx product offering
Product offeringCore offering
BioCorRx delivers substance use disorder treatment and weight loss programs. Its Beat Addiction Recovery Program is an outpatient medication-assisted treatment program that combines proprietary Cognitive Behavioral Therapy (CBT) modules, peer recovery support via mobile application, and physician-prescribed medication. Through subsidiary BioCorRx Pharmaceuticals, the company commercializes LUCEMYRA (lofexidine), an FDA-approved non-opioid oral medication for mitigating opioid withdrawal symptoms, and is developing BICX104, an investigational biodegradable naltrexone implant providing approximately 84 days of sustained therapeutic naltrexone release. The UnCraveRx Weight Loss Program offers medication-assisted weight loss with virtual concierge wellness specialists.
Product overview
BioCorRx is a healthcare solutions company offering two core programs: the Beat Addiction Recovery Program (a substance use disorder recovery program using proprietary CBT modules, peer recovery support, and physician-prescribed medication including naltrexone) and the UnCraveRx Weight Loss Program (a medication-assisted weight loss program with wellness specialists). Through its majority-owned subsidiary BioCorRx Pharmaceuticals Inc., the company is developing BICX104, an investigational biodegradable naltrexone implant for OUD, AUD, and MUD, while also commercializing FDA-approved LUCEMYRA (lofexidine) for opioid withdrawal symptoms.
Differentiator
Problem solved
Functional benefit
Brands
- Beat Addiction Recovery: Substance use disorder recovery program including proprietary Cognitive Behavioral Therapy (CBT) modules and peer recovery support.
- UnCraveRx Weight Loss Program
- LUCEMYRA (lofexidine)
- BICX104
Products and services
- Beat Addiction Recovery Program An outpatient medication-assisted treatment (MAT) program for alcohol and opioid drug addiction, combining BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules with peer recovery support delivered via mobile application, alongside medication prescribed by independent treating physicians. Targeted at independent U.S. treatment centers and physicians who deliver the program to patients.
- UnCraveRx Weight Loss Program A medically assisted weight loss program with virtual health and wellbeing services, providing access to concierge on-demand wellness specialists including nutritionists, fitness experts, and behavioral experts. Targeted at U.S. consumers seeking personalized weight management.
- LUCEMYRA (lofexidine) An FDA-approved oral tablet and central alpha 2-adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. Administered for up to 14 days with dosing guided by symptoms. Generates revenue of $635,224 in Q3 2025 and $948,362 for the nine months ended September 30, 2025.
- BICX104 Biodegradable Naltrexone Implant An investigational biodegradable, long-acting subcutaneous naltrexone implant designed to provide controlled delivery of naltrexone for approximately three months (84 days) following minimally invasive implantation. Being developed for treatment of opioid use disorder (OUD), alcohol use disorder (AUD), and methamphetamine use disorder (MUD) — ClinicalTrials.gov Identifier: NCT04828694. Protected by U.S. Patent No. 12,569,430.
Quantifiable outcome
- 84 days of therapeutic naltrexone plasma concentrations achieved with BICX104 in Phase I clinical trials, compared to 28 days for Vivitrol
- +3 more outcomes
Companies that use BioCorRx
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles4 records
BioCorRx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BioCorRx partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- USWM LLCcoreBioCorRx Pharmaceuticals Inc. acquired LUCEMYRA (lofexidine) from USWM LLC in March 2025. LUCEMYRA is the first and only FDA-approved non-opioid medication indicated to mitigate opioid withdrawal symptoms. Under the agreement terms, USWM LLC retained a portion of future sales up to a capped amount in lieu of direct cash payment, BioCorRx Pharmaceuticals pays a low single digit royalty to USWM LLC, and USWM LLC received shares of common stock and warrants from BioCorRx Inc.
- Crescendo Communications, LLCminorInvestor Relations contact for BioCorRx. Contact at 212-671-1020 x304, [email protected].
- VStock Transfer, LLCminorTransfer Agent for BioCorRx Inc. Located at 18 Lafayette Place, Woodmere, NY 11598, T: 212-828-8436, www.vstocktransfer.com.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
BioCorRx competitors and assessment
Company assessmentDirect peers
- Braeburn Inc. Commercializes Probuphine in the US for OUD; competes in the long-acting implantable addiction treatment space and is a potential commercial partner or competitor for BICX104.
- WW International (Weight Watchers): Operates a medically-adjacent weight management program; competes with BioCorRx's UnCraveRx medication-assisted weight loss program in the consumer weight management segment.
- Alkermes plc: Manufacturer of Vivitrol (injectable naltrexone), the current 28-day standard against which BioCorRx's BICX104 implant is being developed. Both companies target opioid and alcohol use disorder via long-acting naltrexone pharmacology.
- Titan Pharmaceuticals: Developer of Probuphine, the first six-month subcutaneous buprenorphine implant for OUD, with which BioCorRx's biodegradable naltrexone implant shares the long-acting implantable delivery model and partially overlapping addiction science team (Dr. Kate Beebe DeVarney).
- Indivior PLC: Markets Sublocade (monthly buprenorphine injection) and other OUD therapies; a direct competitor in the long-acting medication-assisted treatment market that BioCorRx is targeting with BICX104.
- US WorldMeds (USWM): Original developer of LUCEMYRA (lofexidine), which BioCorRx Pharmaceuticals acquired in March 2025; USWM retains sales economics and royalty on the product BioCorRx now commercializes.
Emerging players
- Workit Health: Provides online MAT and substance use disorder treatment via telemedicine; competes directly with BioCorRx's Beat Addiction Recovery Program in the outpatient/virtual addiction care segment.
- Lionrock Recovery: Offers online counseling and telehealth for substance use disorder, mirroring BioCorRx's CBT-and-peer-support model. Both companies target outpatient recovery through digital means.
- Pear Therapeutics (legacy assets): Pioneered FDA-authorized prescription digital therapeutics (reSET/reSET-O) for substance use disorder; conceptually aligned with BioCorRx's proprietary CBT modules and mobile peer-support application.
- LifeMD, Inc. Direct-to-consumer telehealth platform that includes medically-assisted weight management programs (including GLP-1 pathways); a competing digital channel for UnCraveRx's subscription-based model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
BioCorRx social profiles
Digital presenceBioCorRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioCorRx leadership team
Management profileNumber of profiles
Profiles5 records
BioCorRx subsidiaries and ownership
Company hierarchySubsidiaries1 record
BioCorRx funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioCorRx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioCorRx
What does BioCorRx do?
BioCorRx delivers substance use disorder treatment and weight loss programs. Its Beat Addiction Recovery Program is an outpatient medication-assisted treatment program that combines proprietary Cognitive Behavioral Therapy (CBT) modules, peer recovery support via mobile application, and physician-prescribed medication. Through subsidiary BioCorRx Pharmaceuticals, the company commercializes LUCEMYRA (lofexidine), an FDA-approved non-opioid oral medication for mitigating opioid withdrawal symptoms, and is developing BICX104, an investigational biodegradable naltrexone implant providing approximately 84 days of sustained therapeutic naltrexone release. The UnCraveRx Weight Loss Program offers medication-assisted weight loss with virtual concierge wellness specialists.
Is BioCorRx a public or private company?
BioCorRx is a public company. It is classified as public and is currently operating.
When was BioCorRx founded?
BioCorRx was founded in 2010. It employs 1 to 10 people.
Where is BioCorRx based?
BioCorRx is headquartered in Anaheim, United States, in the North America region.
How does BioCorRx make money?
Three revenue lines are on record. LUCEMYRA (lofexidine) Sales are the primary driver. The others are beat Addiction Recovery Program and unCraveRx Weight Loss Program.
Who are BioCorRx's main competitors?
Direct peers on record are Braeburn Inc., WW International (Weight Watchers), Alkermes plc, Titan Pharmaceuticals, Indivior PLC and US WorldMeds (USWM). Emerging players are Workit Health, Lionrock Recovery, Pear Therapeutics (legacy assets) and LifeMD, Inc..
Does BioCorRx have an API?
No public API is recorded for BioCorRx.
What industry is BioCorRx in?
BioCorRx's product category is Addiction Treatment Services. Its primary akta.pro industry code is HLAFACAE, Residential Substance Use Rehabilitation (Inpatient Rehab), with a secondary code of HLAFALAN, Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring. Its NAICS code is 62142 and its SIC code is 2834.